Cited by

• Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics.

  Markowicz-Piasecka M, Markiewicz A, Darłak P, Sikora J, Adla SK, Bagina S, Huttunen KM. Markowicz-Piasecka M, et al. Neurotherapeutics. 2022 Apr;19(3):942-976. doi: 10.1007/s13311-022-01228-5. Epub 2022 Apr 7. Neurotherapeutics. 2022. PMID: 35391662 Free PMC article. Review.
• Targeting the CNS to treat type 2 diabetes.

  Sandoval DA, Obici S, Seeley RJ. Sandoval DA, et al. Nat Rev Drug Discov. 2009 May;8(5):386-98. doi: 10.1038/nrd2874. Nat Rev Drug Discov. 2009. PMID: 19404312 Review.
• Hybrid pharmacokinetic models to describe anti-HIV nucleoside brain disposition following parent and prodrug administration in mice.

  Gallo JM, Etse JT, Doshi KJ, Boudinot FD, Chu CK. Gallo JM, et al. Pharm Res. 1991 Feb;8(2):247-53. doi: 10.1023/a:1015808624103. Pharm Res. 1991. PMID: 2023876
• Solubilization and stabilization of a benzylpenicillin chemical delivery system by 2-hydroxypropyl-beta-cyclodextrin.

  Pop E, Loftsson T, Bodor N. Pop E, et al. Pharm Res. 1991 Aug;8(8):1044-9. doi: 10.1023/a:1015865209874. Pharm Res. 1991. PMID: 1924158
• Enhanced delivery of ganciclovir to the brain through the use of redox targeting.

  Brewster ME, Raghavan K, Pop E, Bodor N. Brewster ME, et al. Antimicrob Agents Chemother. 1994 Apr;38(4):817-23. doi: 10.1128/AAC.38.4.817. Antimicrob Agents Chemother. 1994. PMID: 8031052 Free PMC article.